- Created on the 12 March, 2017.
Interleukin-17 (IL-17 or IL-17A) is a secreted glycoprotein that has a molecular mass of 35 kDa, it is a 155 amino acid protein that is disulphide-linked. The structure of IL-17 is made up of a signal peptide (approx. 23 amino acids) that is followed by a 123 amino acid chain region which is characteristic of the typical IL-17 family. Interleukin-17 is a pro-inflammatory cytokine which is produced by T-helper cells and is known to be induced by IL-23. In order for it to carry out its function IL-17 needs to bind to a type I cell surface receptor called IL-17R (can be either IL17RA, IL17RB or IL17RC).
In addition to IL-17A, other members of the IL-17 family include IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25) and IL-17F. All members of the IL-17 family display a very similar protein structure, consisting of four highly conserved cysteine residues that are essential for their 3-dimensional shape. These cytokines are also known to be well conserved in mammals, with approx. 62–88% of amino acid conservation between the human and mouse homologs. IL-17 is most notably known for inducing and mediating pro-inflammatory responses, it has also been commonly associated with allergic responses. It has the ability to induce cytokines (IL-1β, IL-6, G-CSF, GM-CSF, TNF-α, TGF-β), chemokines (IL-8, MCP-1 and GRO-α) and prostaglandins (PGE). Interleukin-17 can also acts with IL-22 in order to induce expression of antimicrobial peptide by keratinocytes.
Recent studies have indicated that the IL-23/IL-17 pathway could play a major role in the autoimmune disorder psoriasis. In this condition, immune cells are known to react to inflammatory molecules which have been released within the skin around the joints and scalp. Due to its involvement in immune regulatory functions, there are many IL-17 inhibitors which are being investigated for potential treatments for autoimmune diseases (such as psoriasis, inflammatory bowel disease and rheumatoid arthritis).
Interleukin-17 ELISA kit is designed for analysing in vitro quantitative levels of interleukin-17 (IL-17) in human plasma (EDTA, heparin), serum and cell culture supernatant samples. This assay has a minimum detection limit of < 1.0 pg/ml.
The minimum detection sensitivity level of interleukin-17 (IL-17) using this human interleukin-17 ELISA kit was approximately 1.0 pg/ml. The dynamic assay range for this kit is 31.2 – 2,000 pg/ml.
- IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. (2016) 22 (3): 230-41. Review. Beringer A., et al.
- The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. (2016) 175 (5): 892-901. Review. Speeckaert R., et al.
- Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine. (2015) 75 (2): 207-15. Review. Konya C., et al.
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. Annu Rev Med. (2016) 67: 337-53. Review. Fragoulis G.E., et al.
- Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000. (2015) 69 (1): 142-59. Review. Zenobia C. and Hajishengallis G.
- The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. (2015) 33 (4 Suppl 92): S87-90. Review. Wang K. and Karin M.
- Full Name: Interleukin-17 (IL-17) ELISA Kit
- Reactivity: Human
- Sample Type: Plasma (Heparin, EDTA), Serum, Cell Culture Supernatant
- Sensitivity: < 1.0 pg/ml